Jeremy Hayward-Surry

Savient Pharmaceuticals, Inc. operates as a specialty biopharmaceutical company, which develops, manufactures and markets pharmaceutical products. The company focuses on developing and commercializing KRYSTEXXA for the treatment of chronic gout in adult patients who do not respond to conventional therapy. It also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. The company was founded in 1980 is headquartered in East Brunswick, NJ.

Vitex is a Delaware Corporation incorporated in 1995. Vitex’s scientific and clinical programs originated in anti-infective technologies designed to prevent the spread of infectious disease by blood transfusions. In March of 2005, Vitex merged with Panacos Pharmaceuticals, a private company developing HIV therapeutics with novel mechanisms of action. The merger with Panacos immediately expanded the Vitex pipeline into novel, high value therapeutics. The Panacos team that joined Vitex is recognized for fundamental contributions to HIV biology and drug development

Pall Corp. designs, manufactures, and markets filtration and separation equipment. Its products are used to remove solid, liquid, and gaseous contaminants from a variety of liquids and gases. The firm has Life Sciences and Industrial segments. The Life Sciences segment focuses on developing, manufacturing, and selling products to customers in the medical, biopharmaceuticals, and food and beverage markets. The Industrial segment focuses on developing, manufacturing and selling products to customers in the process technologies, aerospace, and microelectronics markets. The company was founded by David B. Pall on July 31, 1946 and is headquartered in Port Washington, NY.